Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.

Blood
Judith TrotmanConstantine S Tam

Abstract

Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who were either treatment-naïve (TN) or had relapsed/refractory (R/R) disease. Patients had disease requiring treatment per International Workshop on Waldenström Macroglobulinemia (IWWM) criteria. Treatment was 160 mg of oral zanubrutinib twice daily (n = 50) or 320 mg once daily (n = 23). Efficacy endpoints included overall response rate (ORR) and very good partial response/complete response (VGPR/CR) rates per IWWM-6 criteria (with modification of VGPR definition published previously). Between September 2014 and March 2018, 77 patients (24 TN and 53 R/R) began treatment. At a median follow-up of 36.0 months for patients with R/R disease and 23.5 months for TN, 72.7% remained on treatment. Reasons for treatment discontinuation included any adverse events in 13.0% of patients (1 treatment related), disease progression (10.4%), and other (3.9%). The ORR was 95.9%, and the VGPR/CR rate was 45.2%, which increased over time: 20.5% at 6 months, 32.9% at 12 months, and 43.8% at 24 months. Estima...Continue Reading

References

Aug 31, 2012·The New England Journal of Medicine·Steven P TreonZachary R Hunter
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Nov 16, 2012·British Journal of Haematology·Roger G OwenUNKNOWN VIth International Workshop on Waldenström macroglobulinaemia
Apr 9, 2015·The New England Journal of Medicine·Steven P TreonRanjana H Advani
May 24, 2015·Blood·Steven P Treon
Jan 23, 2016·International Journal of Laboratory Hematology·A AlbitarM Albitar
Dec 14, 2016·The Lancet Oncology·Meletios A DimopoulosUNKNOWN iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia
Sep 14, 2017·Leukemia & Lymphoma·Chloe Pek Sang TangConstantine Tam
Jul 26, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonJorge J Castillo

❮ Previous
Next ❯

Citations

Feb 23, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonJorge J Castillo
Oct 30, 2020·Blood·Prashant Kapoor, Steven P Treon
Dec 11, 2020·Expert Review of Hematology·Kenneth J C Lim, Constantine S Tam
Jan 15, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger G Owen
Dec 15, 2020·Platelets·Maan H HarbiMark R Thomas
Feb 12, 2021·Leukemia & Lymphoma·Andrew R BranaganJorge J Castillo
Feb 23, 2021·Therapeutic Advances in Hematology·Ioannis Ntanasis-StathopoulosMeletios A Dimopoulos
Mar 30, 2021·Frontiers in Cell and Developmental Biology·H Yesid EstupiñánC I Edvard Smith
Apr 22, 2021·Current Treatment Options in Allergy·Melanie C Dispenza
Apr 29, 2021·American Journal of Hematology·Jithma P AbeykoonPrashant Kapoor
May 5, 2021·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Soi C LawMaher K Gandhi
Aug 25, 2021·Current Treatment Options in Oncology·Shayna SarosiekJorge J Castillo
Sep 8, 2021·Expert Review of Clinical Pharmacology·Constantine S TamStephen Opat
Sep 25, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Donald C Moore
Oct 26, 2021·Current Treatment Options in Oncology·Lori A Leslie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.